OncoMatch/Clinical Trials/NCT05929612
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Is NCT05929612 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for lymphoma.
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses after that.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: MALT1 translocation (t11:18)
Testing for the MALT1 translocation (t11:18) is strongly recommended if tissue for testing is available.
Disease stage
Required: Stage I, II
Prior therapy
Cannot have received: radiation therapy
Exception: if re-treatment would exceed known gastric or surrounding critical structure (e.g., bowel, spinal cord) tolerance
Patients with a history of radiation to the treated site, if re-treatment would exceed known gastric or surrounding critical structure (e.g., bowel, spinal cord) tolerance.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify